RBP4 and coronary artery disorder: Meanwhile, rosuvastatin can remarkably reduce serum RBP4, hs-CRP, and IL-27 levels, which is of significance for prognosis and improvement of the condition of CHD clinically, and can imply the development and progression of disease more accurately.